Tests izalontamab brengitecan against chemotherapy in lung cancer after EGFR drug failure
Tests izalontamab brengitecan against platinum chemotherapy in adults with EGFR-mutated lung cancer.
Plain-language title generated from the registry record
Registry title: Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Key facts
- Where
- Ahmedabad, Bengaluru, Gurugram, Howrah, Mumbai, Nagpur, and New Delhi, IndiaSee the 9 sites
- Phase
- Phase 2/3
Where in India
- AhmedabadAhmedabad, IndiaNo longer taking part
- AhmedabadAhmedabad, IndiaNo longer taking part
- BengaluruBengaluru, IndiaNot yet recruiting
- GurugramGurugram, IndiaNo longer taking part
- HowrahHowrah, IndiaNo longer taking part
- MumbaiMumbai, IndiaNot yet recruiting
- MumbaiMumbai, IndiaNot yet recruiting
- NagpurNagpur, IndiaNot yet recruiting
- New DelhiNew Delhi, IndiaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07100080
- Record updated
- 9 October 2026
- Original description
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI TherapyRead full original descriptionShow less
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Inclusion: Non-squamous NSCLC, not amenable to treatment in curative intent; Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation); Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting; Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).
Exclusion: Poorly controlled systemic medical conditions; Inadequate organ function and/or bone marrow reserve; Leptomeningeal metastases or spinal cord compression; Other protocol-defined inclusion/exclusion criteria apply.